HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Degree MotionSense ‘Superior Protection’ Claims Idled In NAD Review

This article was originally published in The Tan Sheet

Executive Summary

Higher fragrance content does not equal a more “protective” antiperspirant, the National Advertising Division says in a decision resolving dispute between Degree marketer Unilever and competitor P&G. Flaws in Unilever’s testing design contributed to the recommendation to discontinue or modify the challenged ads.

You may also be interested in...



Old Spice Wins In Challenge Of Art Of Sport’s Claims Made With Racing Deodorant Canisters

Videos featured unmarked red deodorant canister with familiar Old Spice diagonal turquoise banner at its midpoint and a white medallion in the center and a canister with the Art of Sport trade dress, which prevailed in contests in both videos.

US FDA Says White Paper Could Inform Rulemaking For Cosmetic Talc-Asbestos Testing

Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.

US FDA Advises Drug Firms To Test For Benzene Contamination As Root-Cause Investigation Continues

The FDA offers insight into possible sources of benzene contamination in drug products, including aerosol spray propellants, carbomers, or other drug components made from hydrocarbons. Manufacturers that find benzene in drug product batches at levels exceeding 2 ppm should not release the product or, if already in distribution, discuss with the FDA initiating a voluntary recall.

Topics

Related Companies

UsernamePublicRestriction

Register

RS123692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel